Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
HUTCHMED (China) Limited American Depositary Shares · Now $11.40
-5.1% in 7d after detection
Post-detection moves
1h
—
1d
-1.2%
3d
-0.6%
7d
-5.1%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS